=MabVax Therapeutics (MBVX) provides update on MVT-5873 Phase 1 clinical program

Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014.
Headquarters: San Diego, CA
Founded: 1988
mabvax.com


MabVax Therapeutics provides update on MVT-5873 Phase 1 clinical program and expansion of preclinical development pipleline at the ACCR-NCI-EORTC International Conference(

• Company highlights encouraging tumor response data from a Phase 1 trial of HuMab-5B1 (MVT-5873) when used in combination with nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer.
• Positive results from recent HuMab-5B1 preclinical studies demonstrate promise in potential treatment of colon, lung, and small cell lung cancer regardless of mutational status and chemoresistance
• New positive research results summarize the discovery, optimization, and target validation of new fully human antibodies targeting the cancer antigens Tn and sTn expanding Company's valuable preclinical pipeline